Compare Amgen, Inc. (AMGN) vs Prudential Financial Inc (PRU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Prudential Financial Inc — how do they compare? Amgen, Inc. trades at $416.99 (market cap $224.14B), while Prudential Financial Inc trades at $123 (market cap $42.20B). The key difference: Amgen, Inc. is far larger — about 5.3× Prudential Financial Inc's market cap, and Prudential Financial Inc pays the higher dividend (4.58%). Which is the better fit depends on your goals.
| AMGN | PRU | |
|---|---|---|
Market Cap | $224.14B | $42.20B |
Sector | Health | Financials |
52-Week High | $417.20 | $123.93 |
52-Week Low | $271.18 | $92.00 |
Enterprise Value | $267.45B | $70.98B |
Dividend Yield | 2.43% | 4.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $417.44, up 0.06% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong Q2 2026 results, beating EPS estimates and raising full-year guidance, driven by robust product growth. Revenue reached $36.75B in 2025 with a net income margin of 22.95%, though high debt levels remain a focus.
Outlook is positive given earnings momentum and raised guidance, but risks include competitive pressures and a data breach investigation. Analyst consensus is Buy with a $394.69 price target, suggesting near-term consolidation after recent gains. The stock's valuation multiples are elevated relative to historical levels.
Prudential Financial (PRU) trades at $122.63, up 0.43% on the day, with a bullish technical signal from moving averages and recent earnings beats in Q1 and Q2 2026. The company reported Q2 EPS of $4.08, exceeding expectations, driven by strength in PGIM and international segments. Valuation remains attractive with a P/E of 11.09 and P/S of 0.66, while a $1.40 quarterly dividend supports income appeal.
Outlook is cautiously optimistic given earnings momentum and strategic focus on capital-light operations, but risks include sensitivity to interest rates and regulatory changes in key markets like China. Analyst consensus is mixed with a Hold rating predominating, though institutional holdings show increased interest, suggesting potential for upside if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Prudential Financial Inc
Prudential Financial is a large, diversified insurance company offering annuities, life insurance, retirement plan services, and asset management products. While it operates in a number of countries, the vast majority of revenue is generated in the United States and Japan. The company's investment management business, PGIM, contributes approximately 15% of its earnings and has over $1.5 trillion in assets under management. The U.S. businesses are responsible for about 45% of earnings and can be classified into Institutional Retirement Strategies, Individual Retirement Strategies, Group Insurance, Individual Life Insurance, and Assurance IQ. Finally, the international business segment of the company contributes approximately 40% of earnings with a strong market position in Japan.
Read more on PRU →
